What the Study Found (In Plain English)
Published in RMD open (2022), this phase iii randomized trial evaluating human clinical outcomes investigated: Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR). Key clinical takeaway: Overall, RBZ treatment resulted in improvements in pain, fatigue, health-related quality of life and ability to perform work in Bio-IR and/or csDMARD-IR patients with PsA.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (RMD open, 2022-06-15; Phase III Randomized Trial; Rigor 88/100): Overall, RBZ treatment resulted in improvements in pain, fatigue, health-related quality of life and ability to perform work in Bio-IR and/or csDMARD-IR patients with PsA.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.